Concentration and Activity of Lapatinib in Vestibular Schwannomas

This study is currently recruiting participants.
Verified August 2013 by Sidney Kimmel Comprehensive Cancer Center
Sponsor:
Collaborators:
The Children's Tumor Foundation
GlaxoSmithKline
New York University
Ohio State University
House Research Institute
Washington University School of Medicine
Weill Medical College of Cornell University
Massachusetts General Hospital
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00863122
First received: March 13, 2009
Last updated: August 5, 2013
Last verified: August 2013

March 13, 2009
August 5, 2013
June 2009
December 2013   (final data collection date for primary outcome measure)
  • To assess steady-state lapatinib plasma concentrations at the time of surgical resection, 10 (+3) days after oral dosing. [ Time Frame: one year ] [ Designated as safety issue: No ]
  • To assess whether lapatinib can reach a minimum tumor concentration level of >3uM in VS after oral dosing. [ Time Frame: one year ] [ Designated as safety issue: No ]
  • To assess steady-state lapatinib plasma concentrations at the time of surgical resection, 10 (+3) days after oral dosing. [ Designated as safety issue: No ]
  • To assess whether lapatinib can reach a minimum tumor concentration level of >3uM in VS after oral dosing. [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00863122 on ClinicalTrials.gov Archive Site
  • Assess the level of ErbB2 and EGFR phosphorylation and activity of downstream signaling effectors in VS. [ Time Frame: one year ] [ Designated as safety issue: No ]
  • Assess markers of tumor proliferation and cell death in VS after exposure to lapatinib. [ Time Frame: one year ] [ Designated as safety issue: No ]
  • Explore the difference in the concentration of lapatinib achieved in NF2-related versus idiopathic VS. [ Time Frame: one year ] [ Designated as safety issue: No ]
  • Perform NF2 gene mutation analysis via exon scanning and MLPA as well as protein expression in all VS and explore differences between sporadic and NF2 related VS. [ Time Frame: one year ] [ Designated as safety issue: No ]
  • Assess the level of ErbB2 and EGFR phosphorylation and activity of downstream signaling effectors in VS. [ Designated as safety issue: No ]
  • Assess markers of tumor proliferation and cell death in VS after exposure to lapatinib. [ Designated as safety issue: No ]
  • Explore the difference in the concentration of lapatinib achieved in NF2-related versus idiopathic VS. [ Designated as safety issue: No ]
  • Perform NF2 gene mutation analysis via exon scanning and MLPA as well as protein expression in all VS and explore differences between sporadic and NF2 related VS. [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Exploration and Estimation of Intratumoral Concentration and Activity of Lapatinib in Vivo in Vestibular Schwannomas

Tumors can grow on the auditory nerves and can cause hearing loss. A common type of tumor that does this is a vestibular schwannoma (VS), or acoustic neuroma. These tumors are not cancerous. Most often, people have only one VS. Occasionally, people have more than one VS and may have a condition called neurofibromatosis type 2 (NF2).

Because VS can cause hearing loss, many people with VS will have treatment to preserve their hearing. This treatment usually involves surgery or radiation therapy. There are risks to these procedures, and sometimes they do not work to prevent hearing loss. Because surgery and radiation have risks and are not able to help everyone with VS, other methods of treatment are being explored. One area of exploration is looking to see if there is a drug that can be taken that might prevent the VS from growing larger and causing hearing loss, and might possibly even cause the VS to shrink in size.

This study is exploring whether a drug that is approved by the FDA and is currently used to treat breast cancer might also work to treat VS. This study will measure the amount of drug that travels from the bloodstream and arrives at the tumor. This drug is safe and has few side effects. If this drug is shown to reach the tumor, it might be used in the future to treat VS without needing surgery or radiation.

This study is recruiting people who are having surgery for VS. If you are going to have surgery to treat a VS, you may be eligible to participate.

Neurofibromatosis type 2 (NF2) is a rare autosomal dominant genetic disorder with an incidence of approximately 1/40,000. The most common tumor type in NF2 is vestibular schwannoma and the majority of NF2 patients develop progressive hearing loss in adolescence or young adulthood due to bilateral vestibular schwannoma (VS). In addition to hearing loss, VS can cause significant morbidity, and in some cases mortality, due to brain stem compression.

Currently, the only accepted modality for treatment of VS in patients with NF2 is surgical resection. Although surgical resection is effective at tumor reduction, it is often associated with morbid complications such as hearing loss, facial palsy, CSF leaks, chronic headache and infection. In addition, the tumors often recur after surgery. Radiation therapy (RT) has been proposed as an alternative, however, its safety in the NF2 population has not been established and there is concern about long term efficacy. For a distinct population of NF2 patients, surgery and RT at not feasible and no additional therapy is currently available. Hence, a systemic therapy is needed.

Sporadic VS are common with roughly 3,000 new cases per year in the United States and a growing incidence in recent years. These tumors cause unilateral hearing loss, tinnitus, and vertigo. The primary treatment modality for these tumors is surgical resection or radiosurgery. Surgery is associated with the same complications listed above for NF2-related VS. Hence, RT is often offered in place of surgery. Although considered safe in sporadic VS, it may not have good long term efficacy and may complicate future procedures. Again, a systemic therapy that could control tumor progression obviating the need for an invasive procedure is needed.

As the understanding of tumor molecular biology continues to advance, there are an increasing number of attractive targets for VS growth inhibition. EGFR and ErbB2 have been identified as important targets for VS. In a study of 21 sporadic and 17 NF2-related VS samples, both EGFR and ErbB2 were found to be upregulated in the majority of tumors. In addition, an anti-ErbB2 monoclonal antibody reduced schwannoma cell proliferation in vitro. Collectively, this data suggests that abnormal signaling via EGFR and ErbB2 is a major contributor to tumor growth and progression in both sporadic and NF2-related VS, and that inhibition of this signaling pathway can result in decreased tumor growth. Although agents targeting these pathways are commercially available, there is little pre-clinical data to assist in prioritizing which agents to advance to clinical trials. Given the relative rarity of the disorder and the enormous patient, financial and time commitments an efficacy study requires, there is a need to carefully select agents for testing that have the best chance of success.

In this trial, we propose to assess the delivery of lapatinib, a commercially available inhibitor of ErbB2 and EGFR, to VS via tissue sampling at the time of clinically indicated surgery. Demonstrating that lapatinib reaches meaningful intratumoral concentrations is important data to recommend this drug above other small molecule inhibitors for efficacy trials for VS. The primary objective is to determine the steady state concentration of lapatinib in VS in patients with NF2 and in patients with sporadic VS. Patient who are planning to have surgical resection of their tumor for clinical indications will be given lapatinib for 15 days prior to resection. At the time of resection, VS tissue will be assessed for drug concentration and molecular markers of drug activity.

Demonstrating that lapatinib reaches meaningful concentrations within VS would support selecting this agent for investigation in efficacy studies for VS, and tissue-based molecular studies will provide corollary information about the behavior of VS in general and about lapatinib specifically in VS tissue. This may further our understanding of the pathophysiology of VS, the similarities and differences between NF2-related and sporadic VS, and inform the design of subsequent efficacy trials.

Interventional
Phase 0
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
  • Vestibular Schwannoma
  • NF2
  • Neurofibromatosis 2
  • Acoustic Neuroma
  • Auditory Tumor
Drug: lapatinib
1500 mg lapatinib by mouth per day for 10 days
Other Name: Tykerb
  • Experimental: lapatinib
    Subjects will receive lapatinib for 10 days prior to surgery for vestibular schwannoma resection.
    Intervention: Drug: lapatinib
  • No Intervention: control
    Control subjects will not receive any intervention prior to surgery for vestibular schwannoma resection.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
26
Not Provided
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Meet diagnostic criteria for NF2 including presence of bilateral VS or idiopathic VS without evidence of genetic syndrome.
  • VS surgery determined clinically necessary by the treating physician and scheduled within 4 weeks.
  • Normal cardiac left ventricular ejection fraction (LVEF) by multiple-gated acquisition (MUGA) scan or transthoracic echocardiogram.
  • Karnofsky performance status 60% (i.e. the patient must be able to care for himself/herself with occasional help from others).
  • Must have the following hematologic, renal and liver function: Absolute neutrophil count ≥ 1,000/mm³ (unsupported); platelet count ≥ 75,000/mm³ (unsupported); hemoglobin ≥ 8 g/dL (transfusion support allowed); Creatinine ≤ 1.5 times upper limit of normal (ULN) OR glomerular filtration rate ≥ 70 ml/min; Bilirubin ≤ 1.5 times ULN; ALT ≤ 2.5 times ULN.
  • Be able to provide written informed consent.
  • Any neurologic deficits must be stable for ≥ 1 week.
  • Be able to swallow tablets.
  • Subjects with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Women of childbearing potential must have a negative pregnancy test.
  • Suspend the use of P450 inducing or P450 suppressing agents for a minimum of 10 days prior to starting lapatinib.

Exclusion Criteria:

  • Serious concurrent infection or medical illness, which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety.
  • Pregnant or breast-feeding.
  • Receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents, radiation or immunotherapy) within 4 weeks of the first dose of the study drug.
  • Concurrent or prior malignancy, other than curatively treated carcinoma-in-situ or basal cell carcinoma of the skin. Subjects who have been free of disease (any prior malignancy) for five years are eligible for this study.
  • Received cytochrome P450-inducing anticonvulsants (EIADs; e.g., phenytoin, carbamazepine, phenobarbital, primidone, oxcarbazepine) or similar agents (e.g., rifampin) or P450 inhibiting agents (Ketoconazole, Itraconazole, Clarithromycin, Atazanavir, Indinavir, Nefazodone, Nelfinavir, Ritonavir, Saquinavir, Telithromycin, Voriconazole) within 10 days prior to starting lapatinib.
  • Significant gastrointestinal disorder(s)(e.g., Crohn's disease, ulcerative colitis, extensive gastric resection).
  • Neurologic deficits that are rapidly progressing.
  • Known cardiac disease (either arrhythmia or congestive heart failure) requiring treatment.
Both
18 Years and older
No
Contact: Jaishri Blakeley, MD (410) 955-8837 jblakel3@jhmi.edu
United States
 
NCT00863122
J0867, NA_00020841
Not Provided
Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center
  • The Children's Tumor Foundation
  • GlaxoSmithKline
  • New York University
  • Ohio State University
  • House Research Institute
  • Washington University School of Medicine
  • Weill Medical College of Cornell University
  • Massachusetts General Hospital
Principal Investigator: Jaishri O Blakeley, MD Johns Hopkins University
Sidney Kimmel Comprehensive Cancer Center
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP